← All trials
NCT05010564
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2022
- Primary completion
- Mar 29, 2025
- Completion date
- Mar 29, 2040
- First posted
- Aug 18, 2021
- Last posted
- Nov 4, 2021
- Enrollment
- 38
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Baylor UniversityLead sponsor
- Baylor UniversityReponsible party - principal investigator
- Baylor UniversityOverall official - principal investigator
- Baylor UniversityCollaborator
- The University of Texas, DallasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.